Sensyne's 'MagnifEye' gets MHRA special use authorisation
Clinical artificial intelligence (AI) company Sensyne Health announced on Friday that its ‘MagnifEye’ software application, which uses AI to automate the accurate reading and analysis of lateral flow diagnostic tests, has been granted special use authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA).
The AIM-traded firm said the authorisation was specifically for the use of MagnifEye with the Innova Covid-19 lateral flow self-test kit, which was the platform originally used to test the MagnifEye technology as part of the NHS Digital pilot study.
It said the Innova lateral flow test was used as it was currently the only test to have received temporary MHRA derogation, and would continue to be used with MagnifEye under the authorisation of special use.
The company said it was also pursuing a wider authorisation for the use of MagnifEye with other manufacturers' kits and for other medical indications, and was working with its exclusive licence and technology partner Excalibur Healthcare Services.
“MagnifEye has demonstrated that it has the potential to play an important role in Covid-19 disease surveillance with increased lateral flow test reading accuracy and greater certainty over correct test interpretation,” said chief executive officer Lord Drayson.
“We believe our technology also demonstrates the value of AI in the analysis of medical images, a field that Sensyne has deep expertise in.”
At 0827 BST, shares in Sensyne Health were up 2.02% at 166.8p.